AvH contact: Lenny Van Steenhuyse
Beneficial interest: 12.4%
DISCO Pharmaceuticals uses groundbreaking proteomics technology to map the cancer cell surfaceome. has pioneered the initial surfaceome mapping for Small Cell Lung Cncer (SCLC) and Colorectal Cancer (CRC). The company is currently advancing multiple ADC candidates toward studies that will enable submission for Investigational New Drug (IND) status.